Trial Profile

A Phase 1b/2, Open-Label, Dose Finding, and Expansion Study of the Bcl-2 Inhibitor BGB-11417 in Patients With Myeloid Malignancies

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 17 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Azacitidine (Primary) ; Azacitidine (Primary) ; Sonrotoclax (Primary) ; Posaconazole
Indications Acute myeloid leukaemia; Myelodysplastic syndromes; Myeloproliferative disorders
Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
Sponsors BeOne Medicines

Most Recent Events

29 Oct 2024 Planned End Date changed from 1 Aug 2025 to 8 Feb 2028.
29 Oct 2024 Planned primary completion date changed from 1 Dec 2023 to 8 Feb 2028.
13 Dec 2022 Preliminary results (As of 1 June 2022, n=51) assessing safety and efficacy of Bgb-11417, presented at the 64th American Society of Hematology Annual Meeting and Exposition.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com